NASDAQ:TXMD TherapeuticsMD Q1 2025 Earnings Report $2.02 +0.01 (+0.50%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast TherapeuticsMD EPS ResultsActual EPS-$0.06Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ATherapeuticsMD Revenue ResultsActual Revenue$0.39 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATherapeuticsMD Announcement DetailsQuarterQ1 2025Date5/13/2025TimeAfter Market ClosesConference Call DateTuesday, May 13, 2025Conference Call Time12:00AM ETUpcoming EarningsTherapeuticsMD's Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) TherapeuticsMD Earnings HeadlinesCritical Comparison: Tilray Brands (NASDAQ:TLRY) & TherapeuticsMD (NASDAQ:TXMD)October 5 at 8:14 AM | americanbankingnews.comTherapeuticsMD (NASDAQ:TXMD) and Shineco (NASDAQ:SISI) Head to Head AnalysisOctober 5 at 5:44 AM | americanbankingnews.comSee How You Could Qualify for the Fastest Second Citizenship as an American TodayA new law has opened a fast-track path to second citizenship for millions of qualified Americans, with some completing the process in as little as 7 weeks. Judy from California says she was shocked at how quickly her citizenship came through. Many Americans may already qualify without realizing it. Jennifer Stevens, Executive Editor of International Living, explains how to check your eligibility.October 6 at 1:00 AM | International Living (Ad)TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gainsJune 5, 2026 | marketwatch.comTherapeuticsMD Reports Quarterly Profit, Evaluates Strategic AlternativesMay 12, 2026 | tipranks.comTherapeuticsMD Announces First Quarter 2026 Financial ResultsMay 12, 2026 | businesswire.comSee More TherapeuticsMD Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email. Email Address About TherapeuticsMDTherapeuticsMD (NASDAQ:TXMD) was a pharmaceutical company focused on developing and commercializing products for women’s health. The company’s portfolio addressed contraception, menopause, and related reproductive-health needs, primarily in the United States. Its principal products included ANNOVERA, a reusable vaginal contraceptive system; IMVEXXY, a vaginal estradiol insert for treating moderate-to-severe dyspareunia associated with menopause; and BIJUVA, an oral hormone therapy containing estradiol and progesterone for certain menopausal symptoms. TherapeuticsMD also developed prenatal vitamins and other products intended to support women’s health. TherapeuticsMD was formerly publicly traded on the Nasdaq under the symbol TXMD. The company later underwent significant financial and strategic changes, including a bankruptcy restructuring and the transfer or sale of rights to certain products. Accordingly, its historical product portfolio and corporate status may differ from information associated with the former public company.View TherapeuticsMD ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lamb Weston’s Turnaround Is Starting to Look RealAI Chip Demand Gives Linde a New Growth CatalystInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02 Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
